Regulatory Pathway Strategy

Best fit for this support

The engagement should be scoped around the current state of the work, the intended decision or milestone, the source package, and the sponsor's approval responsibilities.

Emerging companies defining a US route to market

Assess classification, authority center, possible application types, evidence expectations, key precedents, uncertainty, and the next regulatory decision

Programs with a novel or combination technology

Structure the questions that must be resolved when product characteristics do not map cleanly to a familiar pathway or predicate model.

Teams reconsidering an inherited strategy

Independently review pathway assumptions, intended use or indication, claims, evidence gaps, comparable products, authority feedback, and development implications.

When you may need Regulatory Pathway support

when needed

The product is technically defined, but its regulatory classification, authority center, application route, or development implications remain uncertain.
A medical device team is comparing 510(k), De Novo, premarket approval, or another pathway and needs a documented basis for the recommendation
A drug or biologic program needs to frame an IND, NDA, BLA, 505(b)(2), abbreviated, expedited, or other route without confusing pathway selection with application preparation.
The intended use, indication, claims, target population, technology, or product configuration may materially change the pathway or evidence burden.
Comparable products, predicates, precedents, guidances, or authority feedback appear inconsistent or incomplete.
The sponsor needs a focused question set and evidence package for an FDA interaction before committing significant development resources.

Problems this service helps address

Problems

The service is most valuable when the team can identify the specific control gap, decision, deliverable, or recovery need rather than requesting generic capacity.

The pathway is selected from one product analogy without testing differences in intended use, technology, risk, claims, evidence, or authority history.
Regulatory classification, development strategy, reimbursement, commercial claims, and submission planning are discussed as one decision rather than connected but distinct workstreams.
Uncertainty is hidden inside a single recommendation instead of being expressed through options, assumptions, evidence gaps, and decision triggers.
The program begins costly testing before confirming whether the data answer the likely regulatory questions.
Authority meeting questions are broad and do not seek decisions that can change the development plan.

Scope of support

Scope

The exact scope depends on the maturity of the work, the quality of the inputs, the sponsor’s procedures, the review model, and the target milestone.

Review the product, intended use or indication, target population, technology, mechanism, configuration, development stage, evidence, target market, and business objective.
Assess preliminary classification, authority center or jurisdiction, potential regulatory routes, application types, and material uncertainties.
Research and compare relevant statutes, regulations, official guidance, databases, product precedents, predicates, and public authority decisions when applicable.
Develop pathway options with assumptions, advantages, limitations, evidence implications, decision points, and recommended next actions.
Map the selected or preferred pathway to high-level clinical, nonclinical, CMC, quality, software, human factors, performance, and postmarket implications as applicable.
Prepare focused regulatory questions, briefing inputs, and meeting strategy for authority confirmation when needed.
Document the recommendation, unresolved risks, sponsor decisions, and triggers that would require the pathway to be reassessed.

Typical deliverables

Deliverables

Deliverables should be confirmed at kickoff and linked to defined sponsor decisions, review cycles, and downstream handoffs.

A regulatory classification and pathway assessment memorandum with assumptions and limitations.
An options comparison covering potential routes, evidence implications, precedents, uncertainty, advantages, and risks.
A recommended pathway and decision roadmap identifying what is known, what requires confirmation, and what could change the route.
A high-level evidence and development implication map linked to the proposed pathway.
Authority-meeting objectives, questions, background inputs, and decision log when included in scope.
A pathway-risk register and next-step plan for sponsor approval

Client inputs that help the work move efficiently

Client inputs

The sponsor does not need every detail finalized before kickoff, but approved decisions, open questions, source owners, reviewers, and deadlines must be distinguishable.

Product description, technology, mechanism, configuration, components, software or diagnostic role, intended use or indication, claims, and target population.
Development stage, existing clinical, nonclinical, analytical, performance, CMC, quality, human-factors, and safety evidence.
Target market and jurisdiction, commercial objective, key milestone, funding or partner assumptions, and relevant timeline constraints.
Comparable products, potential predicates, prior analyses, competitor or precedent information, authority correspondence, and meeting outcomes.
Known uncertainties, alternative configurations, planned claims, development options, and decisions the sponsor needs to make.
Named regulatory, clinical, technical, quality, business, and executive decision owners.

How the engagement works

Process

1. Confirm the purpose, current state, intended use, milestone, stakeholders, responsibilities, systems or vendors, and agreed deliverables.

2. Review available source materials, prior decisions, procedures, evidence, and open issues; issue a focused gap and dependency list.

3. Develop the work plan, specifications, document, assessment, or control package included in scope.

4. Coordinate review through named sponsor and cross-functional decision owners and maintain a controlled open-item and comment process.

5. Perform the agreed technical, quality, consistency, or operational checks and document remaining risks or limitations.

6. Prepare the approved handoff, implementation, submission, remediation, archive, or next-step package as defined in scope.

Quality, regulatory, and operational considerations

Considerations

The work should remain proportionate to the risk and intended use, follow the sponsor’s controlled process, and preserve clear sponsor decision authority.

Use current official sources and product-specific facts; avoid applying a pathway solely because a similar technology used it.
Separate confirmed requirements, reasonable interpretations, assumptions, and questions requiring authority feedback
Show how intended use, indication, claims, risk, configuration, target population, and evidence can change the route.
Treat pathway strategy as a living decision that may need reassessment as the product, evidence, or authority feedback evolves.
Do not promise classification, clearance, approval, designation, or authority agreement.

Engagement options

Complete work package

BioBoston leads the defined scope from assessment and planning through drafting or execution, review, quality control, and handoff.

Targeted module or rescue

BioBoston addresses a specific section, decision, backlog, finding, vendor issue, or stalled deliverable without expanding the engagement unnecessarily.

Independent review or sponsor-side support

BioBoston provides an objective second-line review, oversight role, or embedded specialist while the sponsor or another vendor retains primary execution.

Related BioBoston services

RELATED SERVICES

Submission Planning

Translate the selected pathway into an executable application plan, readiness model, content inventory, and integrated schedule.

Product Development Planning

Connect the pathway and evidence implications to the broader clinical development plan, endpoints, protocol concepts, vendors, and budget assumptions.

FDA Briefing Book Writing

Develop the controlled meeting package once objectives, questions, positions, evidence, and authority strategy are approved.

Labeling Support

Align proposed labeling and claims with the approved regulatory position, evidence, risks, and product use.

Match the expertise to the project

Expertise

Pathway experience should match the product category, technology, intended use or indication, jurisdiction, authority center, development stage, and the specific classification or application question

Related resources

RESOURCES

Explore the following resources for additional insights and information relevant to this service.

Regulatory Pathway Decision Framework

A planned tool for product facts, classification, possible routes, precedent, evidence, uncertainty, decision triggers, and authority questions.

510(k) vs. De Novo Pathway Comparison

A planned educational comparison of predicate logic, novelty, risk, evidence, uncertainty, and questions that may require FDA feedback.

FDA Meeting Question-Development Checklist

A planned checklist for decision-focused objectives, questions, sponsor positions, evidence, alternatives, and requested feedback.

Frequently asked questions

FAQs

What is a regulatory pathway assessment?

It is a structured analysis of product facts, classification, authority jurisdiction, possible application routes, relevant precedents, evidence implications, uncertainty, and the decisions needed to select or confirm a route.

Can BioBoston determine whether a device should use 510(k), De Novo, or PMA?

BioBoston can assess the available facts, potential predicates, risk, novelty, claims, evidence, and public sources and develop a recommendation. FDA ultimately determines classification and pathway questions.

Does pathway strategy include preparation of the submission?

No. Pathway strategy selects or clarifies the route. Submission Planning creates the application plan, and Submission Writing develops the assigned documents.

Can BioBoston support an FDA meeting to confirm the pathway?

Yes. Support may include meeting strategy, objectives, questions, evidence framing, briefing inputs, rehearsal, and response planning. The exact authority interaction and sponsor representation role must be defined.

When should the pathway be reassessed?

Reassessment may be appropriate after material changes to the product, technology, intended use,
indication, claims, population, evidence, risk profile, manufacturing approach, comparable products, or authority feedback.

Does BioBoston guarantee FDA agreement with the recommended pathway?

No. BioBoston can provide a reasoned, source-supported assessment and help frame authority questions, but the sponsor owns its decisions and FDA or another authority makes the regulatory determination.

Clarify the route before the next development commitment

A productive first discussion identifies the product facts, intended use or indication, evidence, target market, current assumptions, prior authority feedback, and the decision at stake. BioBoston can then define the pathway assessment, option comparison, or authority-meeting support.

Regulatory Pathway Strategy for Drugs, Biologics, Medical Devices, and Diagnostics

Tell Us What Support You Need